IIA Logo_Segment-Beauty.png
SBLA Beauty Liquid Facelift Wand Awarded “Serum Product Of The Year” In 2024 Beauty Innovation Awards
14 nov. 2024 08h02 HE | Beauty Innovation Awards
LOS ANGELES, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The 2024 Beauty Innovation Awards, an independent recognition platform highlighting the most innovative companies, services, and products in the highly...
Oral Proteins & Peptides Market
Oral Proteins & Peptides Market Research: Semaglutide, Linaclotide, Calcitonin,GLP-1 Receptor Agonist, GEP, CGRP, Diabetes, Gastroenterology, Genetic Disorder - Global Forecast to 2029
08 nov. 2024 11h32 HE | Research and Markets
Dublin, Nov. 08, 2024 (GLOBE NEWSWIRE) -- The "Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic...
Peptide Therapeutics Market
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More
14 oct. 2024 11h15 HE | Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Peptide...
Peptide Therapeutics Market
Peptide Therapeutics Market and Industry Forecast 2024-2032: Total Revenues Forecast to Reach $86.9 Billion by 2032, Dominated by Pfizer, AstraZeneca, Roche, Novo Nordisk and Teva Pharmaceuticals
10 oct. 2024 06h34 HE | Research and Markets
Dublin, Oct. 10, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics Market Report by Type, Type of Manufacturer, Synthesis Technology, Routes of Administration, Application, and Region 2024-2032"...
Arch_Twitter_Logo.png
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
01 oct. 2024 14h24 HE | Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
treos logo.jpg
New Meta-Analysis Shows Treos Bio’s Promiscuous Epitopes in Their Off-The-Shelf Colorectal Cancer Immunotherapy Produce Stronger Immune Response than Traditional Epitopes
09 sept. 2024 16h16 HE | Treos Bio Corp.
LONDON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Treos Bio announced the results of a meta-analysis from three clinical trials evaluating its investigational off-the-shelf immunotherapy, PolyPEPI1018, for...
22157.jpg
Peptide Therapeutics Market Forecast to 2028: Projected to Grow by $17.85 Billion, Driven by a Strong Pipeline and Favorable Reimbursement Policies
26 août 2024 07h56 HE | Research and Markets
Dublin, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The "Global Peptide Therapeutics Market 2024-2028" report has been added to ResearchAndMarkets.com's offering.The peptide therapeutics market is forecasted...
image1 (1).png
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
16 juil. 2024 07h30 HE | Evaxion Biotech
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art...
Global Custom Antibody Market
Global Custom Antibody (mAbs, pAbs, rAbs) Market Research 2024-2030: Service (Development, Purification, Fragmentation, Labeling), Source (Rabbit, Mice), Application (Research, Therapeutics)
19 juin 2024 10h01 HE | Research and Markets
Dublin, June 19, 2024 (GLOBE NEWSWIRE) -- The "Global Custom Antibody Market by Service (Development, Purification, Fragmentation, Labeling), Type (mAbs, pAbs, rAbs), Source (Rabbit, Mice),...
treos logo.jpg
At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer
03 juin 2024 07h00 HE | Treos Bio Corp.
Treos Bio reports promising survival results for chemo-free PolyPEPI1018 cancer vaccine combined with Roche's PD-L1 inhibitor in MSS mCRC at 2024 ASCO